Trade Gilead ^GILD

Thrivent Financial for Lutherans Sells 238,111 Shares of Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Stock Position Trimmed by China Universal Asset Management Co. Ltd.

Kentucky Retirement Systems Decreases Stake in Gilead Sciences, Inc. $GILD - Daily Political

6,279 Shares in Gilead Sciences, Inc. $GILD Purchased by Rexford Capital Inc. - Daily Political

Why Arcus Biosciences (RCUS) Is Down 15.4% After Ending Key Gastric Cancer Trial And Pivoting Pipeline

Is Earlier Yescarta Use in Lymphoma Altering The Investment Case For Gilead Sciences (GILD)?

Gilead Sciences, Inc. $GILD Stock Position Decreased by Benjamin Edwards Inc. - Markets Daily

Gilead Sciences, Inc. $GILD Shares Sold by Benjamin Edwards Inc.

AQR Capital Management LLC Has $272.21 Million Stake in Gilead Sciences, Inc. $GILD

Ameriprise Financial Inc. Boosts Holdings in Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Shares Purchased by Adage Capital Partners GP L.L.C.

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $133.00 - Markets Daily

Morgan Stanley Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - Stock Observer

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $150.00 - Stock Observer

BlueCrest Capital Management Ltd Buys Shares of 13,553 Gilead Sciences, Inc. $GILD - Daily Political

Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer

Stock Traders Buy Large Volume of Gilead Sciences Call Options (NASDAQ:GILD)

Gilead Sciences Sees Unusually High Options Volume (NASDAQ:GILD) - Markets Daily

Arcus Biosciences Shares Drop 12% After Discontinuing Phase 3 STAR-221 Trial

Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment - Update | Morningstar

Arcus Biosciences And Gilead Discontinue Phase 3 STAR-221 Study In Cancer Due To Futility

Gilead, Arcus scrap late-stage trial of cancer drug combo - Yahoo News Canada

Gilead Sciences, Inc. $GILD Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

Sei Investments Co. Raises Stock Holdings in Gilead Sciences, Inc. $GILD

NewEdge Advisors LLC Has $11.81 Million Stock Position in Gilead Sciences, Inc. $GILD

Alliancebernstein L.P. Sells 809,531 Shares of Gilead Sciences, Inc. $GILD

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $151.00 at Morgan Stanley - Daily Political

Fota's Fergal Harte: 'We're having debates about food menus because of the cost of beef'

Arcus shifts effort, bears down on would-be 'anchor' in RCC | BioWorld

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - Daily Political

CIBC Asset Management Inc Sells 28,874 Shares of Gilead Sciences, Inc. $GILD

The Manufacturers Life Insurance Company Sells 95,568 Shares of Gilead Sciences, Inc. $GILD - Daily Political

Gilead Sciences (GILD) Gets a Buy from Wells Fargo | Markets Insider

Gilead Sciences, Inc. $GILD Stake Decreased by Intact Investment Management Inc. - Daily Political

Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD)

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $133.00 at HSBC

Wells Fargo & Company Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

Kalaris Therapeutics Inc. $KLRS Shares Sold by Gilead Sciences Inc.

30,000 Shares in Gilead Sciences, Inc. $GILD Bought by Diadema Partners LP

Lombard Odier Asset Management Switzerland SA Raises Position in Gilead Sciences, Inc. $GILD - Markets Daily

State Street Corp Sells 335,515 Shares of Gilead Sciences, Inc. $GILD

Ossiam Sells 15,066 Shares of Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Shares Sold by Investment Management Corp of Ontario - Stock Observer

Daiwa Securities Group Inc. Has $40.24 Million Stake in Gilead Sciences, Inc. $GILD - Daily Political

- 98% reduction in HSV-2 shedding rate, >99% reduction in

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

35,296 Shares in Gilead Sciences, Inc. $GILD Bought by SVB Wealth LLC

WINTON GROUP Ltd Invests $5.02 Million in Gilead Sciences, Inc. $GILD - Stock Observer

Steroid therapy is linked to lower incidence of acute kidney injury in patients with severe alcohol-associated hepatitis

- Benefits Seen Regardless of Eligibility for Previous Stand

Federated Hermes Inc. Sells 1,885,664 Shares of Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Position Decreased by Brown Advisory Inc.

Gilead Sciences, Inc. $GILD Shares Sold by Baird Financial Group Inc.

Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates

California Public Employees Retirement System Has $462.95 Million Stock Holdings in Gilead Sciences, Inc. $GILD - Stock Observer

Pharmaceutical Stocks To Watch Today - December 6th - Markets Daily

- Initial Results from Kite-753, Optimized with Novel Manufa

- 96% Overall Response Rate, 74% Stringent Complete Response

Arrowstreet Capital Limited Partnership Grows Position in Gilead Sciences, Inc. $GILD

First Trust Advisors LP Sells 1,512,069 Shares of Gilead Sciences, Inc. $GILD - Stock Observer

Marshall Wace LLP Grows Position in Gilead Sciences, Inc. $GILD

Epoch Investment Partners Inc. Grows Holdings in Gilead Sciences, Inc. $GILD - Markets Daily

Dodge & Cox Lowers Stake in Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Shares Bought by CW Advisors LLC

Marshall Wace LLP Has $216.29 Million Position in Gilead Sciences, Inc. $GILD - Stock Observer

Epoch Investment Partners Inc. Has $95.16 Million Stake in Gilead Sciences, Inc. $GILD - Stock Observer

VestGen Advisors LLC Decreases Stake in Gilead Sciences, Inc. $GILD - Zolmax

VestGen Advisors LLC Lowers Holdings in Gilead Sciences, Inc. $GILD

Gilead Sciences (NASDAQ:GILD) Director Sells $625,400.00 in Stock - Markets Daily

Gilead Sciences, Inc. $GILD Shares Acquired by Guggenheim Capital LLC

Groupe la Francaise Has $3.92 Million Stake in Gilead Sciences, Inc. $GILD

Gilead (GILD) Valuation After Fresh Buy Rating and Extended Biktarvy Exclusivity Boost Investor Confidence

Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion

Invesco Ltd. Purchases 3,394,330 Shares of Gilead Sciences, Inc. $GILD - Zolmax

Invesco Ltd. Buys 3,394,330 Shares of Gilead Sciences, Inc. $GILD

Jeffrey Bluestone Sells 5,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences (NASDAQ:GILD) Director Sells $356,515.50 in Stock

Loomis Sayles & Co. L P Boosts Stake in Gilead Sciences, Inc. $GILD - Markets Daily

Shelton Capital Management Sells 3,380 Shares of Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Shares Bought by Loomis Sayles & Co. L P - Stock Observer

Northwestern Mutual Wealth Management Co. Has $9.94 Million Stake in Gilead Sciences, Inc. $GILD - Daily Political

Gilead Sciences (NASDAQ:GILD) Director Jeffrey Bluestone Sells 5,000 Shares - Stock Observer

Gilead Sciences (NASDAQ:GILD) CEO Sells $1,265,400.00 in Stock - Stock Observer

Panagora Asset Management Inc. Has $175.96 Million Stock Position in Gilead Sciences, Inc. $GILD - Markets Daily

Railway Pension Investments Ltd Reduces Holdings in Gilead Sciences, Inc. $GILD

India's AIDS fight at a crossroads as breakthrough drug faces patent barriers - India Today

2,222 Shares in Gilead Sciences, Inc. $GILD Purchased by Valued Retirements Inc. - Daily Political

Gilead Sciences, Inc. $GILD Shares Sold by OMERS ADMINISTRATION Corp - Daily Political

Gilead (GILD) Earns Buy Rating at Truist as HIV Franchise Continues to Deliver

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

The Week Ahead: ISM services, SMCI

Week ahead: Wall Street’s Magnificent Seven earnings are up

Week ahead: Earnings season climax

Week ahead: RBA poised to hike?

Week ahead: Megacap tech and 1-in-3 Dow components set to report

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk